Brief: Basilea Announces Agreement With Innoviva Specialty Therapeutics For Commercialization Of Zevtera In The United States
Dec 16 (Reuters) - Basilea Pharmaceutica AG Allschwil
BSLN.S :
* BASILEA ANNOUNCES AGREEMENT WITH INNOVIVA SPECIALTY
THERAPEUTICS
FOR THE COMMERCIALIZATION OF ANTIBIOTIC ZEVTERA® (CEFTOBIPROLE)
IN THE UNITED STATES
* BASILEA PHARMACEUTICA AG ALLSCHWIL - TO RECEIVE $4 MILLION
UPFRONT PAYMENT, UP TO $223 MILLION IN MILESTONES
Source text: ID:nGNXRFJGH
Further company coverage: BSLN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Basilea Pharmaceutica AG, Allschwil
See all newsBrief: Basilea Pharmaceutica - Strong Cresemba Sales In Europe Trigger USD 37.5 Mln Milestone Payment
Basilea seen up after raising 2026 guidance
Brief: Basilea Expects 2026 Operating Profit Of CHF 115 Mln
Brief: Basilea Reports Presentation Of New Data For Fosmanogepix, Isavuconazole And Ceftobiprole At IDWeek 2026
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments